165 related articles for article (PubMed ID: 30290160)
1. Inhibition of catechol-O-methyltransferase in the cynomolgus monkey by opicapone after acute and repeated administration.
Kitajima T; Mizote S; Bonifácio MJ; Umemura T; Yoneda K; Moser P; Soares-da-Silva P; Tanaka M
Neuropharmacology; 2018 Dec; 143():282-288. PubMed ID: 30290160
[TBL] [Abstract][Full Text] [Related]
2. A single- and multiple-dose study to investigate the pharmacokinetics and pharmacodynamics of opicapone, a novel COMT inhibitor, in rat.
Gonçalves D; Alves G; Fortuna A; Bonifácio MJ; Soares-da-Silva P; Falcão A
Neuropharmacology; 2017 Oct; 125():146-155. PubMed ID: 28734868
[TBL] [Abstract][Full Text] [Related]
3. Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.
Bonifácio MJ; Sutcliffe JS; Torrão L; Wright LC; Soares-da-Silva P
Neuropharmacology; 2014 Feb; 77():334-41. PubMed ID: 24148813
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of opicapone, a third-generation COMT inhibitor, after single and multiple oral administration: A comparative study in the rat.
Gonçalves D; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
Toxicol Appl Pharmacol; 2017 May; 323():9-15. PubMed ID: 28322896
[TBL] [Abstract][Full Text] [Related]
5. Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys.
Bonifácio MJ; Sousa F; Soares-da-Silva P
Eur J Pharmacol; 2021 Feb; 892():173742. PubMed ID: 33220276
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor.
Almeida L; Rocha JF; Falcão A; Palma PN; Loureiro AI; Pinto R; Bonifácio MJ; Wright LC; Nunes T; Soares-da-Silva P
Clin Pharmacokinet; 2013 Feb; 52(2):139-51. PubMed ID: 23248072
[TBL] [Abstract][Full Text] [Related]
7. Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
Rocha JF; Ferreira JJ; Falcão A; Santos A; Pinto R; Nunes T; Almeida L; Soares-da-Silva P
Clin Pharmacol Drug Dev; 2016 May; 5(3):232-40. PubMed ID: 27163503
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.
Bonifácio MJ; Torrão L; Loureiro AI; Palma PN; Wright LC; Soares-da-Silva P
Br J Pharmacol; 2015 Apr; 172(7):1739-52. PubMed ID: 25409768
[TBL] [Abstract][Full Text] [Related]
9. Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects.
Rocha JF; Almeida L; Falcão A; Palma PN; Loureiro AI; Pinto R; Bonifácio MJ; Wright LC; Nunes T; Soares-da-Silva P
Br J Clin Pharmacol; 2013 Nov; 76(5):763-75. PubMed ID: 23336248
[TBL] [Abstract][Full Text] [Related]
10. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
Rocha JF; Falcão A; Santos A; Pinto R; Lopes N; Nunes T; Wright LC; Vaz-da-Silva M; Soares-da-Silva P
Eur J Clin Pharmacol; 2014 Sep; 70(9):1059-71. PubMed ID: 24925090
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson's disease.
Svetel M; Tomić A; Kresojević N; Kostić V
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):353-360. PubMed ID: 29345156
[TBL] [Abstract][Full Text] [Related]
12. Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA.
Lees AJ; Ferreira J; Rascol O; Reichmann H; Stocchi F; Tolosa E; Poewe W
Expert Rev Neurother; 2017 Jul; 17(7):649-659. PubMed ID: 28580819
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study.
Pinto R; l'Hostis P; Patat A; Homery MC; Falcão A; Nunes T; Rocha JF; Soares-da-Silva P
Clin Pharmacol Drug Dev; 2015 Nov; 4(6):454-62. PubMed ID: 27137718
[TBL] [Abstract][Full Text] [Related]
14. Opicapone pharmacokinetics and pharmacodynamics comparison between healthy Japanese and matched white subjects.
Falcão A; Rocha JF; Santos A; Nunes T; Soares-da-Silva P
Clin Pharmacol Drug Dev; 2016 Mar; 5(2):150-61. PubMed ID: 27138028
[TBL] [Abstract][Full Text] [Related]
15. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease.
Ferreira JJ; Rocha JF; Falcão A; Santos A; Pinto R; Nunes T; Soares-da-Silva P
Eur J Neurol; 2015 May; 22(5):815-25, e56. PubMed ID: 25649051
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic Comparison of Capsule and Tablet Formulations of Opicapone in Healthy Japanese Subjects: Phase 1 Study.
Nomoto M; Takeda A; Iwai K; Nishimura A; Hattori N
Clin Pharmacol Drug Dev; 2021 Feb; 10(2):173-179. PubMed ID: 32459885
[TBL] [Abstract][Full Text] [Related]
17. Effect of moderate liver impairment on the pharmacokinetics of opicapone.
Rocha JF; Santos A; Falcão A; Lopes N; Nunes T; Pinto R; Soares-da-Silva P
Eur J Clin Pharmacol; 2014 Mar; 70(3):279-86. PubMed ID: 24271646
[TBL] [Abstract][Full Text] [Related]
18. Effect of Opicapone Tablets on Levodopa and 3-O-Methyldopa Pharmacokinetics in Healthy Japanese Subjects: Phase 1 Study.
Nomoto M; Takeda A; Iwai K; Nishimura A; Hattori N
Clin Pharmacol Drug Dev; 2021 Feb; 10(2):180-189. PubMed ID: 32416054
[TBL] [Abstract][Full Text] [Related]
19. Opicapone: A Review in Parkinson's Disease.
Scott LJ
Drugs; 2016 Sep; 76(13):1293-1300. PubMed ID: 27498199
[TBL] [Abstract][Full Text] [Related]
20. Opicapone (Ongentys): A New COMT Inhibitor for the Treatment of Parkinson's Disease.
St Onge E; Vanderhoof M; Miller S
Ann Pharmacother; 2021 Sep; 55(9):1159-1166. PubMed ID: 33233916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
